Table 3.

Hazard ratio (95% confidence interval) of breast cancer-specific death and any cause death for HR+/HER2− breast cancer patients who did not receive Oncotype DX test compared to those who received the test, 2010–2014, 17 SEER registries

		Breast cancer-specific survival		Overall survival
		HR	95% CI	HR	95% CI
N0	0–72 mon	1.92	1.56, 2.35	2.03	1.81, 2.28
	0–36 mon	2.25	1.73, 2.93	2.25	1.95, 2.59
	37–72 mon	1.47	1.07, 2.04	1.67	1.37, 2.03
N1	0–72 mon	1.86	1.39, 2.49	1.71	1.41, 2.08
	0–36 mon	2.13	1.45, 3.12	1.89	1.49, 2.40
	37–72 mon	1.54	0.98, 2.41	1.40	1.00, 1.96

Within the stratum defined by diagnosis year, lymph node status, tumor size, and tumor grade, patients who received Oncotype DX test and those who did not were matched on propensity score which was calculated based on age, race/ethnicity, marital status, insurance, surgery, and radiation therapy

HR hormone receptor, HER2 human epidermal growth factor receptor 2, N0 with negative axillary lymph node, N1 with 1–3 positive ipsilateral axillary lymph nodes, HR hazard ratio, CI confidence interval